Clinicopathological Profile of Low-Grade B Cell Non-Hodgkin Lymphoma in Tertiary Health Care in West Java Indonesia

  • Etis Primastari Anatomical Pathology Department, Medicine Faculty, Padjadjaran University/ Hasan Sadikin Central General Hospital, Bandung, West Java, Indonesia
  • Bethy Suryawathy Hernowo, MD, PhD Anatomical Pathology Department, Medicine Faculty, Padjadjaran University/ Hasan Sadikin Central General Hospital, Bandung, West Java, Indonesia
  • Birgitta Maria Dewayani, MD Anatomical Pathology Department, Medicine Faculty, Padjadjaran University/ Hasan Sadikin Central General Hospital, Bandung, West Java, Indonesia

Abstract

Background: Low-grade B cell Non-Hodgkin lymphomas (NHL) are a group of lymphomas that are predominantly indolent and make up approximately 50% of all malignant lymphomas. Initial therapy for low-grade B cell LNH has an overall response rate of between 85-94% and a refractory rate of 6-10%. Few reports have been published regarding the clinicopathological characteristics of non-Hodgkin lymphoma cases, especially low-grade B cell types. This research aims to determine the clinicopathological profile of low-grade B cell type non-Hodgkin lymphoma cases.


Method: This research is a descriptive study using cross-sectional methods. The sample consisted of 40 low-grade B cell type NHL cases from January 2015 to June 2020 at Hasan Sadikin Hospital, Bandung. Clinicopathological data, including age, sex, location of the tumor (nodal or extranodal), stage, B symptoms, and response to therapy, were taken from the patients’ medical records. Data were categorized into 2 groups based on response to initial therapy.


Results and Discussion: Of the 40 cases diagnosed with low-grade B cell type NHL, 55% responded to initial therapy. From the non-response group, 61.1% were stage II and 72.2% exhibited B symptoms. There were no significant differences in age, sex, tumor location (nodal or extranodal), stage, or B symptoms in the response and non-response groups.


Conclusion: In this study, 45% of patients with low-grade B cell type NHL did not respond to initial therapy. There was no statistically significant difference in the clinicopathological profiles of the response and non-response groups to initial therapy in cases of low-grade B cell type NHL.


Keywords: Non-Hodgkin Lymphoma, low-grade B cell lymphoma, therapy response, clinicopathological

Keywords: Non-Hodgkin Lymphoma, low-grade B cell lymphoma, therapy response, clinicopathological

Downloads

Download data is not yet available.

Author Biographies

Etis Primastari, Anatomical Pathology Department, Medicine Faculty, Padjadjaran University/ Hasan Sadikin Central General Hospital, Bandung, West Java, Indonesia

Anatomical Pathology Department, Medicine Faculty, Padjadjaran University/ Hasan Sadikin General Hospital, Bandung, Indonesia

Bethy Suryawathy Hernowo, MD, PhD, Anatomical Pathology Department, Medicine Faculty, Padjadjaran University/ Hasan Sadikin Central General Hospital, Bandung, West Java, Indonesia

Anatomical Pathology Department, Medicine Faculty, Padjadjaran University/ Hasan Sadikin General Hospital, Bandung, Indonesia

Birgitta Maria Dewayani, MD, Anatomical Pathology Department, Medicine Faculty, Padjadjaran University/ Hasan Sadikin Central General Hospital, Bandung, West Java, Indonesia

Anatomical Pathology Department, Medicine Faculty, Padjadjaran University/ Hasan Sadikin General Hospital, Bandung, Indonesia

References

1. Quintanilla-Martinez L. The 2016 updated WHO classification of lymphoid neoplasias. Hematological Oncology. 2017; 35(S1):37–45.
2. Piñeros M, ZNaor A, Marcos-Gragera R, Steliarova-Foucher E. Global patterns and trends in the incidence of non-Hodgkin lymphoma. Cancer causes & control. 2019 May; 30(5):489–99.
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018 Nov 1; 68(6):394–424.
4. The Global Cancer Observatory. Indonesia Population Fact Sheet [Internet]. IARC WHO; 2018. Available from: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf
5. Cömert P, Yıldız A, Yıldırım M, Afacan Öztürk HB, Pala Ç, Albayrak M, et al. Prognostic Factors in Patients with Low-Grade Nonhodgkin Lymphoma. Indian Journal of Hematology and Blood Transfusion. 2019 Aug 6; Available from: https://doi.org/10.1007/s12288-019-01168-9
6. Freedman A. Follicular lymphoma: 2018 update on diagnosis and management. American Journal of Hematology. 2018 Feb 1;93(2):296–305.
7. Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. American Journal of Hematology. 2019 Jun 1; 94(6):710–25.
8. Bron D, Meuleman N. Marginal zone lymphomas: second most common lymphomas in older patients. Current opinion in oncology. 2019; 31(5):386–93.
9. Kang J, Hong JY, Suh C. Clinical features and survival outcomes of patients with lymphoplasmacytic lymphoma, including non-IgM type, in Korea: a single-center experience. Blood Res. 2018 Sep; 53(3):18997.
10. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. J Natl Compr Canc Netw. 2015 Mar; 13(3):326–62.
11. Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, et al. NCCN Guidelines Version 4.2019 B cell Lymphoma. National Comprehensive Cancer Network; 2019. Available from: www.nccn.org
12. Ninkovic S, Lambert J. Non-Hodgkin lymphoma. Medicine. 2017 May; 45(5):297–304.
13. Perry AM, Diebold J, Nathwani BN, MacLennan KA, Müller-Hermelink HK, Bast M, et al. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. Haematologica. 2016/06/27 ed. 2016 Oct; 101(10):1244–50.
14. Ciobanu A, Stanca O, Triantafyllidis I, Lupu A. Indolent lymphoma: diagnosis and prognosis in medical practice. Maedica (Bucur). 2013 Sep; 8(4):338–42.
15. Mukkamalla S, Taneja A, Malipeddi D. Chronic Lymphocytic Leukemia. In: StatPearls Publishing; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470433/
16. Sharma R, Cunningham D, Smith P, Robertson G, Dent O, Clarke SJ. Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients--analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO. BMC Cancer. 2009 May 18; 9:153–153.
17. Walewski J, Paszkiewicz-Kozik E, Michalski W, Rymkiewicz G, Szpila T, Butrym A, et al. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. British Journal of Haematology [Internet]. 2019 Dec 2. Available from: https://doi.org/10.1111/bjh.16264
Statistics
44 Views | 19 Downloads
How to Cite
1.
Primastari E, Hernowo B, Dewayani B. Clinicopathological Profile of Low-Grade B Cell Non-Hodgkin Lymphoma in Tertiary Health Care in West Java Indonesia. JDDT [Internet]. 15Dec.2020 [cited 21Jan.2021];10(6-s):89-1. Available from: http://jddtonline.info/index.php/jddt/article/view/4632